New Gene Therapy Platform May Reduce Obesity in Mice

This experimental non-viral platform reduced weight in juvenile mice, marking a potential step for future gene therapy research.

Updated on Oct. 27, 2026 in Weight Loss

Isometric editorial illustration of an abstract geometric nanoparticle structure, representing modern non-viral gene therapy research technology. — Addition Therapeutics has presented early-stage data on PRINT, a non-viral gene therapy platform that successfully reduced weight in mice models. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies prioritize developing genetic cures for rare diseases over broader metabolic health treatments?

Addition Therapeutics has shared preliminary data on a new non-viral gene-addition platform called PRINT. The research, presented at the ESGCT Annual Congress, shows the technology successfully reduced body weight in juvenile mice and addressed markers of Fabry disease.

Why it matters

This technology represents a potential new approach to gene therapy by using non-viral, RNA-only methods to treat metabolic conditions like hypothalamic obesity. While the results are promising in mouse models, the findings remain preliminary and have not yet been tested in human patients.

This preclinical study evaluated the PRINT platform in mice, demonstrating 30% body weight suppression and an 80% reduction in lyso-Gb3 levels across various organs. Further research is required to determine if these findings translate to human clinical trials.

The players

Addition Therapeutics

A biotechnology company based in South San Francisco focused on developing gene-addition technologies for metabolic diseases.

The details

The PRINT platform utilizes lipid nanoparticle (LNP) delivery to introduce genetic material into cells without using viral vectors. It employs an R2 retrotransposase to facilitate RNA-mediated insertion of transgenes into the genome. To manage potential risks, researchers included a small-molecule-inducible off switch, which successfully lowered protein levels by approximately 90% in testing.

October 27-30, 2026: The ESGCT Annual Congress takes place in Hamburg, Germany.
October 29, 2026: Addition Therapeutics delivered the oral and poster presentations regarding the PRINT platform.

Health Landscape

This research contributes to the broader development of non-viral gene-addition technologies, which seek to provide more controllable alternatives to conventional viral gene therapies. The effort to move beyond viral vectors is a major focus in current genetic medicine.

Readers should be aware that these gene-addition developments are in early, preclinical stages and are not currently available for clinical use. Any concerns regarding metabolic health or potential new treatment options should always be directed to a physician or specialist.

The takeaway

The PRINT platform suggests that RNA-mediated gene addition could one day address complex metabolic conditions. Keep following long-term research updates to understand how these early-stage technologies eventually transition toward potential clinical trials.